Valeritas appoints Erick Lucera as CFO
Mr. Lucera brings to Valeritas over twenty years of operational and investment experience in biotechnology, specialty pharmaceutical and medical technology companies.
Mr. Lucera currently serves as Chief Financial Officer of Viventia Bio, a late-stage oncology company that filed for an initial public offering in October 2015.
Prior to that, he served as Vice President, Corporate Development at Aratana Therapeutics.
Previously, he was Vice President, Corporate Development at Sunshine Heart while the Company completed its U.S. initial public offering.
Prior to his corporate operational experience, Mr. Lucera spent over fifteen years in investment management focused on the Life Sciences sector at Eaton Vance, the Triathlon Life Sciences Fund at Intrepid Capital and Independence Investments.
He began his career in the Philadelphia office of Price Waterhouse & Co. (now PwC).
He holds a CPH from Harvard University, an MS from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations. ■
LATEST MOVES FROM New Jersey
- New Jersey Resources names Maureen Borkowski to board
- Milestone Scientific appoints Daniel Goldberger as CEO
- Celldex changes management team
- Pacira Pharmaceuticals appoints Mark I. Froimson to board
- CytoSorbents appoints Eric G. Mortensen as CMO
More inside POST